Vanda Pharmaceuticals Inc. (LON:0LKB)
London flag London · Delayed Price · Currency is GBP · Price in USD
7.35
-0.11 (-1.44%)
At close: Feb 11, 2026

Vanda Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
216.11198.77192.64254.38268.68
Revenue Growth (YoY)
8.72%3.18%-24.27%-5.32%8.27%
Cost of Revenue
13.0411.3114.824.2825.63
Gross Profit
203.06187.46177.84230.1243.05
Selling, General & Admin
237.95146.41112.88136.49124.05
Research & Development
109.2774.4376.8285.7775.36
Amortization of Goodwill & Intangibles
7.017.272.091.521.48
Operating Expenses
354.23228.12191.8223.77200.89
Operating Income
-151.17-40.66-13.956.3342.17
Other Non Operating Income (Expenses)
12.5210.7511.492.011.85
EBT Excluding Unusual Items
-138.65-29.92-2.468.3444.01
Gain (Loss) on Sale of Investments
-6.998.82.96-1.65
Pretax Income
-138.65-22.926.3411.342.36
Income Tax Expense
81.83-4.023.835.039.21
Net Income
-220.47-18.92.516.2833.15
Net Income to Common
-220.47-18.92.516.2833.15
Net Income Growth
---60.02%-81.07%42.06%
Shares Outstanding (Basic)
5958575656
Shares Outstanding (Diluted)
5958585757
Shares Change (YoY)
1.34%1.03%1.01%0.11%3.14%
EPS (Basic)
-3.74-0.330.040.110.60
EPS (Diluted)
-3.74-0.330.040.110.58
EPS Growth
---63.64%-81.03%38.09%
Free Cash Flow
--20.48-88.2531.3163.66
Free Cash Flow Per Share
--0.35-1.530.551.12
Gross Margin
93.96%94.31%92.32%90.45%90.46%
Operating Margin
-69.95%-20.46%-7.24%2.49%15.69%
Profit Margin
-102.02%-9.51%1.30%2.47%12.34%
Free Cash Flow Margin
--10.30%-45.81%12.31%23.69%
EBITDA
-143.1-32.53-10.949.0645.01
EBITDA Margin
-66.22%-16.36%-5.68%3.56%16.75%
D&A For EBITDA
8.078.133.012.732.84
EBIT
-151.17-40.66-13.956.3342.17
EBIT Margin
-69.95%-20.46%-7.24%2.49%15.69%
Effective Tax Rate
--60.42%44.47%21.75%
Revenue as Reported
216.11198.77192.64254.38268.68
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.